Conference call and webcast (in English) at 3:00 pm CET (10:00 am EDT) NIH grant of 15million USD received PQ912 Phase 2b core program prepared HALLE (SAALE), […]
HALLE (SAALE), Germany, 21 March 2019 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish […]
Study to Evaluate Safety and Efficacy of Drug Seeking to Treat Those with Mild Cognitive Impairment or Mild Dementia HALLE (SAALE), Germany and San Diego, […]
HALLE (SAALE), Germany, 12 March 2019 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
HALLE (SAALE), Germany, 5 February 2019 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
HALLE (SAALE), Germany, 18 December 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
HALLE (SAALE), Germany, 04 December 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
HALLE (SAALE), Germany, 29 November 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]
Probiodrug AG to Publish its Third Quarter 2018 Business Update on November 29, 2018 HALLE (SAALE), Germany, 22 November 2018 – Probiodrug AG (Euronext […]